Clinical trials: Patients at Risk for Thrombosis
Venous Thromboembolism
A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The study is designed to collect and evaluate Dabigatran Etexilate (DE) safety in the context of routine anticoagulation care provided in the European Union (EU)/European Economic Area (EEA) for children under 2 years of age.
- Trial name
- DaPaR (NCT05536791)
- Testing
- Dabigatran Etexilate (DE)
- Where
- 6 sites in Germany, Netherlands and 2 more
- Sponsor
- Boehringer Ingelheim
Pulmonary Embolism, Trauma
RIPT Feasibility Trial
The risk of venous thromboembolism (VTE) is very high in trauma patients, secondary to tissue injury, venous status from immobilization, and thrombophilia.
- Conditions
- Pulmonary Embolism, Trauma, Venous Thromboembolism
- Trial name
- RIPT (NCT03070834)
- Testing
- Cook 'Celect' retrievable inferior vena cava filter
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Arteriosclerosis
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
RATIONALE: Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
- Trial name
- NCT00050817
- Testing
- clopidogrel (SR25990)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 15,603 people
- Sponsor
- Sanofi
Patients Hospitalized for More Than 48 Hours, Acute Medical Illness
Incidence and Risk Factors of Venous Thrombosis of the Lower Limbs After Hospitalization in Medical Patients at Risk
In Tunisia, the available data are limited regarding the incidence of venous thrombosis of the lower limbs (TVMI) post-hospitalization, whether symptomatic or subclinical.
- Trial name
- MTE (NCT05512923)
- Where
- Tunisia
- Volunteers
- 2,000 people
- Sponsor
- University of Monastir
Venous Thromboembolism, Cancer
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism [VTE] in cancer patients at high risk for VTE and…
- Trial name
- SAVE-ONCO (NCT00694382)
- Testing
- Semuloparin sodium
- Where
- 411 sites in United States, Argentina and 47 more
- Volunteers
- 3,212 people
- Sponsor
- Sanofi
Bleeding, Thrombosis
Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery
Patients who have undergone placement of coronary stents require dual antiplatelet therapy with Plavix and aspirin to prevent the serious complication of in-stent thrombosis.
- Trial name
- NCT00653601
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Venous Thromboembolism
Retrospective Study to Review Patients at Risk for VTE at Hospital Discharge
An investigator initiated study exploring VTE prophylaxis at the time of hospital discharge.
- Trial name
- NCT00604370
- Volunteers
- 2,500 people
- Sponsor
- Brigham and Women's Hospital
Cancer, Deep Venous Thrombosis
Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism
Cancer patients are at increased risk of deep venous thrombosis and pulmonary embolism, collectively termed venous thromboembolism (VTE).
- Conditions
- Cancer, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MICA (NCT02095925)
- Where
- 7 sites in France, Italy and 2 more
- Volunteers
- 900 people
- Sponsor
- Harry R. Buller
Acute Coronary Syndromes
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a…
- Trial name
- NCT02415400
- Testing
- Apixaban, vitamin K antagonist, Acetylsalicylic acid
- Where
- 626 sites in United States, Argentina and 35 more
- Volunteers
- 4,614 people
- Sponsor
- Bristol-Myers Squibb
Stroke
PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.
The purpose of the study is to determine the effectiveness and safety of LMWH postoperative bridging therapy (standard of care) versus postoperative placebo bridging therapy (experimental arm)for patients with mechanical heart…
- Trial name
- NCT00432796
- Testing
- Dalteparin
- Where
- 8 sites in Canada, India
- Volunteers
- 1,473 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Venous Thromboembolism
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
- Trial name
- NCT05966740
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Obesity, Venous Thrombosis
Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
Deep vein thrombosis(DVT) is a common complication in hospitalized medical patients. Consensus guidelines recommend using medications such as heparin or low-molecular-weight heparins (LMWH) to prevent DVT in these patients.
- Conditions
- Obesity, Venous Thrombosis, Anticoagulants
- Trial name
- NCT00585182
- Testing
- Enoxaparin 0.5 mg/kg once daily
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Utah
Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke
Registry on WATCHMAN Outcomes in Real-Life Utilization
The WATCHMAN LAA Closure Technology is designed to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism.
- Trial name
- EWOLUTION (NCT01972282)
- Testing
- WATCHMAN Left Atrial Appendage Closure
- Where
- 47 sites in Belgium, France and 11 more
- Volunteers
- 1,025 people
- Sponsor
- Boston Scientific Corporation
Neoplasms
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein…
- Trial name
- NCT02555878
- Testing
- Rivaroxaban
- Where
- 151 sites in United States, Belgium and 8 more
- Volunteers
- 841 people
- Sponsor
- Janssen Research & Development, LLC
Venous Thromboembolism, Deep-Vein Thrombosis
Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism
The presence of clots in the veins of arms and/or legs or lungs of Cancer patients decreases their quality of life, delays their treatment and may cause death.
- Conditions
- Venous Thromboembolism, Deep-Vein Thrombosis, Pulmonary Embolism, Cancer
- Trial name
- REMARK (NCT01602445)
- Where
- 5 sites in Canada
- Volunteers
- 700 people
- Sponsor
- Ottawa Hospital Research Institute
Patients at Risk for Thrombosis
Randomized Comparison of Warfarin Dosing Quality Between the Hamilton Nomogram and a Commercial Computer System
Randomized comparison of warfarin dosing quality between the Hamilton nomogram and a commercial computer system. Hypothesis: Mean TTR of patients managed with the commercial computer system is non-inferior to management with the…
- Trial name
- NCT01024452
- Testing
- DAWN AC, Hamilton Nomogram
- Where
- Canada
- Volunteers
- 1,298 people
- Sponsor
- Population Health Research Institute
Deep Vein Thrombosis, Pulmonary Embolus
VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism
This is a prospective, multicenter single arm, nonrandomized study that will include 150 patients at a maximum of 20 investigational sites. It is estimated that it may take 13 months to complete enrollment.
- Trial name
- VERITAS (NCT01787773)
- Testing
- Veniti Inferior Vena Cava Filter
- Where
- 2 sites in Australia, New Zealand
- Sponsor
- Veniti
Myocardial Ischemia, Acute Coronary Syndrome
Myeloid-Related Protein in Evaluation of Acute Chest Pain in the Emergency Departement
The purpose of the study is the evaluation of multiple biomarkers related to acute coronary syndromes, including myeloid-related protein 8/14 (MRP 8/14), along with established clinical markers, for early diagnosis and risk…
- Conditions
- Myocardial Ischemia, Acute Coronary Syndrome, Myocardial Infarction, Coronary Occlusion
- Trial name
- MyRiAD (NCT00657436)
- Where
- Switzerland
- Volunteers
- 403 people
- Sponsor
- University of Zurich
Coronary Artery Disease
Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS)
Attenuated plaque ≥ 5mm by intravascular ultrasound(IVUS) was reported to be high risk for distal embolism in Acute coronary syndrome(ACS).
- Trial name
- VAMPIRE3 (NCT01460966)
- Testing
- Filtrap™ + Thrombus aspiration catheter, Thrombus aspiration catheter
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Yokohama City University Medical Center
Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to…
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism
- Trial name
- eVTE (NCT06232551)
- Testing
- EHR (electronic health record) alert, No EHR (electronic health record) alert
- Where
- United States
- Volunteers
- 152,000 people
- Sponsor
- Scott C. Woller, MD